

## Product datasheet for **TR302828**

### **NYX Human shRNA Plasmid Kit (Locus ID 60506)**

#### **Product data:**

<b>Product Type:</b>	shRNA Plasmids
<b>Product Name:</b>	NYX Human shRNA Plasmid Kit (Locus ID 60506)
<b>Locus ID:</b>	60506
<b>Synonyms:</b>	CLRP; CSNB1; CSNB1A; CSNB4; NBM1
<b>Vector:</b>	pRS (TR20003)
<b>E. coli Selection:</b>	Ampicillin
<b>Mammalian Cell Selection:</b>	Puromycin
<b>Format:</b>	Retroviral plasmids
<b>Components:</b>	NYX - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 60506). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
<b>RefSeq:</b>	<a href="#">NM_022567</a> , <a href="#">NM_022567.1</a> , <a href="#">NM_022567.2</a> , <a href="#">BC112242</a>
<b>UniProt ID:</b>	<a href="#">Q9GZU5</a>
<b>Summary:</b>	The product of this gene belongs to the small leucine-rich proteoglycan (SLRP) family of proteins. Defects in this gene are the cause of congenital stationary night blindness type 1 (CSNB1), also called X-linked congenital stationary night blindness (XLCSNB). CSNB1 is a rare inherited retinal disorder characterized by impaired scotopic vision, myopia, hyperopia, nystagmus and reduced visual acuity. The role of other SLRP proteins suggests that mutations in this gene disrupt developing retinal interconnections involving the ON-bipolar cells, leading to the visual losses seen in patients with complete CSNB. [provided by RefSeq, Oct 2008]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).